Dark

SPRO
Spero Therapeutics, Inc. Common Stock
stock NASDAQ

At Close

Jun 4, 2025 3:59:52 PM EDT

2.67USD+1.136%(+0.03)2,655,102

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jun 5, 2025 8:46:30 AM EDT

2.59USD-2.632%(-0.07)42,470

After-hours

Jun 4, 2025 4:55:30 PM EDT

2.67USD0.000%(0.00)5,854

OverviewOptionsHistoricalExchangesShortsNews

Jan 19, 2022

08:44AM EST Spero Awarded Up To Addl $12.9 Mln By BARDA To Support Development Of Tebipenem Pivoxil In Pediatric Patients RTTNews

08:07AM EST Spero Therapeutics Wins Up To Added $12.9M By Biomedical Advanced R&D Authority (BARDA) To Support Development Of Orally Administered Tebipenem Pivoxil In Pediatric Patients Benzinga

08:05AM EST Spero Therapeutics Awarded up to an Additional $12.9 Million by GlobeNewswire Inc

Jan 4, 2022

11:38AM EST FDA Lifts Clinical Hold On Spero Therapeutics' Lung Infection Program Benzinga

08:43AM EST Spero Therapeutics, Inc. (SPRO) announced Tuesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 trial of SPR720, Spero's investigational oral product candidate being developed for nontuberculous mycobacterial (NTM) disease. RTTNews

08:28AM EST Spero Therapeutics Reports Lifting Of FDA Clinical Trial Hold On SPR720 RTTNews

08:06AM EST Spero Therapeutics Reports FDA Clinical Hold On SPR720 Lifted Benzinga

08:05AM EST Spero Therapeutics, Inc.(Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 trial of SPR720, Speros investigational oral product candidate being developed for nontuberculous mycobacterial (NTM) disease. GlobeNewswire Inc

Jan 3, 2022

02:51PM EST Spero Therapeutics Shares Move Higher; Co Reports In Form 4 Filing 10% Owner Aquilo Capital Buys 250,493 Shares At Average Price Of $15.42/Share Benzinga

02:50PM EST Spero Therapeutics Shares Move Higher; Co Reports In Form 4 Filing Aquilo Capital Buys 250,493 Shares At Average Price Of $15.42/Share Benzinga

08:56AM EST Spero Therapeutics, Inc. (SPRO), said on Monday that the U.S. Food and Drug Administration or FDA has granted priority review designation and confirmed a substantive review of the New Drug Application or NDA, for tebipenem HBr oral tablets. RTTNews

08:09AM EST Spero Therapeutics Announces FDA Acceptance And Priority Review Of New Drug Application For Tebipenem HBr For Treatment Of Complicated Urinary Tract Infections Including Pyelonephritis Benzinga

08:05AM EST Spero Therapeutics Announces FDA Acceptance and Priority Review of GlobeNewswire Inc

Nov 17, 2021

08:05AM EST Spero Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc

Nov 10, 2021

05:41PM EST Spero Therapeutics Q3 EPS $(0.70) Misses $(0.66) Estimate, Sales $3.06M Miss $4.47M Estimate Benzinga

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 3, 2021

09:11AM EDT Spero Therapeutics 10%+ Owner Aquilo Capital, L.P. Reported Purchase of 150,000 Shares @ Avg Price of $17.53 in Form 4 Filing on Tuesday Benzinga

08:05AM EDT Spero Therapeutics to Provide Business Update and Report Third GlobeNewswire Inc

Oct 28, 2021

08:05AM EDT Spero Therapeutics Submits New Drug Application to U.S. FDA for GlobeNewswire Inc

Oct 12, 2021

08:05AM EDT Spero Therapeutics Appoints Kathleen Tregoning to its Board of GlobeNewswire Inc

Oct 9, 2021

11:20AM EDT The Past Week's Notable Insider Buys Included Asana, Designer Brands, Evergy And More Benzinga

Oct 1, 2021

04:01PM EDT Spero Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 1, 2021 Benzinga

06:11AM EDT Oppenheimer Downgrades Spero Therapeutics to Perform Benzinga

Sep 30, 2021

03:00PM EDT Spero Therapeutics Inks Revenue Interest Financing Agreement With HealthCare Royalty Partners Benzinga

08:04AM EDT Spero Therapeutics Enters Into A Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners For Up To $125M Benzinga

08:00AM EDT Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest GlobeNewswire Inc

Sep 16, 2021

08:05AM EDT Spero Therapeutics to Present Data at IDWeek 2021 GlobeNewswire Inc

Sep 7, 2021

08:05AM EDT Spero Therapeutics to Present at Three Upcoming Investor Conferences GlobeNewswire Inc

Aug 31, 2021

04:26PM EDT Spero Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Aug 5, 2021

05:07PM EDT Recap: Spero Therapeutics Q2 Earnings Benzinga

04:37PM EDT Spero Therapeutics Q2 EPS $(0.63) Beats $(0.77) Estimate, Sales $5.15M Beat $4.03M Estimate Benzinga

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 30, 2021

04:33PM EDT Spero Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Jul 7, 2021

04:01PM EDT Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare GlobeNewswire Inc

Jul 5, 2021

06:45AM EDT China's Everest Medicines announced Monday that its licensing partner Spero Therapeutics, Inc. (SPRO) entered into a regional licensing agreement with Pfizer Inc. (PFE) for SPR206 in territories excluding U.S. and Asia. RTTNews

06:07AM EDT Spero Therapeutics Enters Licensing Agreement With Pfizer For SPR206 In Ex-U.S. And Ex-Asia Territories RTTNews

06:05AM EDT Everest Medicines Announces that Spero Therapeutics Entered into Licensing PR Newswire

Jul 2, 2021

04:01PM EDT Spero Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Jul 1, 2021

10:41AM EDT Shares of Spero Therapeutics, Inc. (SPRO) are climbing more than 14% Thursday morning at $15.97. RTTNews

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

06:38AM EDT Spero Therapeutics Shares Trading Up 26% Premarket After Company Announced on Wednesday a $40M Equity Investment from Pfizer and Licensing Agreement for SPR206 Benzinga

Jun 30, 2021

06:46PM EDT Spero Therapeutics Announces $40 Million Equity Investment from GlobeNewswire Inc

Jun 16, 2021

06:47AM EDT Spero Therapeutics Kick Starts Two SPR206 Trials For Bronchoalveolar Lavage, Renal Impairment Benzinga

Jun 15, 2021

04:02PM EDT Spero Therapeutics Announces Initiation Of Bronchoalveolar Lavage And Renal Impairment Clinical Trials Of SPR206 Benzinga

04:01PM EDT Spero Therapeutics Announces the Initiation of Bronchoalveolar GlobeNewswire Inc

Jun 9, 2021

04:58PM EDT Spero Therapeutics ClincialTrials.gov Study Record Detail 'Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis' Benzinga

May 28, 2021

05:36PM EDT Spero Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

May 18, 2021

07:44AM EDT The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO Benzinga

May 17, 2021

04:06PM EDT Spero Therapeutics Awarded up to $23M By The National Institute of Allergy and Infectious Diseases to Support the Development of SPR206 Benzinga

04:01PM EDT Spero Therapeutics Awarded up to $23 Million by the National GlobeNewswire Inc

May 13, 2021

08:00AM EDT Spero Therapeutics to Participate at the Berenberg Conference USA GlobeNewswire Inc

May 6, 2021

04:10PM EDT Spero Therapeutics Q1 EPS $(0.66) Misses $(0.64) Estimate, Sales $7.30M Beat $3.16M Estimate Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

Apr 30, 2021

04:32PM EDT Spero Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Mar 11, 2021

04:24PM EST Spero Therapeutics Q4 EPS $(1.31) Misses $(0.74) Estimate, Sales $1.90M Miss $3.67M Estimate Benzinga

04:07PM EST Tebipenem HBr advancing towards NDA submission in the second half of 2021 GlobeNewswire Inc

08:19AM EST The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga

03:35AM EST Earnings Scheduled For March 11, 2021 Benzinga

Mar 3, 2021

08:30AM EST Spero Therapeutics to Provide Business Update and Report Fourth GlobeNewswire Inc

Feb 25, 2021

08:30AM EST Spero Therapeutics to Present at Investor Conferences in March GlobeNewswire Inc

Feb 5, 2021

08:19AM EST Spero Therapeutics Says FDA Placed Clinical Hold On Phase 2a Clinical Trial Of SPR720 RTTNews

08:09AM EST Spero Shares To Resume Trade At 8:30 a.m. EST Benzinga

08:02AM EST UPDATE: Spero Says Decision For Clinical Hold 'based on a recommendation from Spero's Safety Review Board (SRB), following review of data from an ongoing toxicology study of SPR720 in adult non-human primates' Benzinga

08:02AM EST Spero Therapeutics Reports FDA Placed Clinical Hold On Phase 2a Trial Of Oral Antimicrobial Agent For Nontuberculous Mycobaterial Pulmonary Disease, Cites Dosing In Trial As Precautionary Measure Benzinga

08:00AM EST Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial GlobeNewswire Inc

07:55AM EST Spero Shares Halted News Pending Benzinga

Jan 29, 2021

05:17PM EST Spero Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Jan 22, 2021

08:07AM EST 10 Biggest Price Target Changes For Friday Benzinga

06:23AM EST HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $40 Benzinga

Jan 21, 2021

08:00AM EST Spero Therapeutics Announces Issuance of Allowance for a U.S. GlobeNewswire Inc

Dec 30, 2020

08:16AM EST The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data Benzinga

Dec 29, 2020

08:09AM EST The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 18, 2020

07:48AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data Benzinga

07:45AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data Benzinga

Dec 17, 2020

08:13AM EST Spero Therapeutics Appoints Sath Shukla As CFO RTTNews

08:10AM EST The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga

08:02AM EST Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer Benzinga

08:00AM EST Spero Therapeutics, Inc.(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment ofSatyavrat Sath Shukla, CFA, as Chief Financial Officer, effective as of January 4, 2021. GlobeNewswire Inc

Dec 16, 2020

11:18AM EST Berenberg Initiates Coverage On Spero Therapeutics with Buy Rating, Announces Price Target of $47 Benzinga

08:30AM EST Spero Therapeutics Added to the NASDAQ Biotechnology Index GlobeNewswire Inc

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 10, 2020

08:03AM EST Spero Therapeutics Announces First Patient Dosed With SPR720 In Phase 2a Clinical Trial In Patients With Nontuberculous Mycobacterial Pulmonary Disease Benzinga

08:00AM EST Spero Therapeutics Announces First Patient Dosed with SPR720 in GlobeNewswire Inc

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 4, 2020

08:04AM EST The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs Benzinga

Dec 2, 2020

08:30AM EST Spero Therapeutics, Inc.(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment ofTamara Joseph, J.D., L.L.M., as Chief Legal Officer, effective as of today. GlobeNewswire Inc

07:35AM EST The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod Benzinga

Dec 1, 2020

08:08AM EST The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga

Nov 30, 2020

05:01PM EST Spero Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

09:09AM EST Spero Therapeutics to Present at the Evercore ISI HealthCONx GlobeNewswire Inc

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

Nov 23, 2020

08:02AM EST 10 Biggest Price Target Changes For Monday Benzinga

06:27AM EST HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $33 Benzinga

Nov 19, 2020

08:17AM EST The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway Benzinga

Nov 13, 2020

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 11, 2020

07:38AM EST The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga

Nov 5, 2020

05:00PM EST Spero Therapeutics Q3 EPS $(0.86) Beats $(0.87) Estimate, Sales $4.00M Beat $3.20M Estimate Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 3, 2020

08:37AM EST Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RTTNews

08:32AM EST Spero Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 29, 2020

08:00AM EDT Spero Therapeutics to Provide Business Update and Report Third GlobeNewswire Inc

Oct 16, 2020

08:35AM EDT Spero Therapeutics Reports Will Present Data For All Pipeline Programs At IDWeek 2020 Oct. 21-25 Benzinga

08:30AM EDT Spero Therapeutics to Present Data for All Pipeline Programs at GlobeNewswire Inc

Sep 30, 2020

04:59PM EDT Spero Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Sep 29, 2020

11:23AM EDT Evercore ISI Group Initiates Coverage On Spero Therapeutics with Outperform Rating, Announces Price Target of $70 Benzinga

10:19AM EDT Shares of Spero Therapeutics Inc. (SPRO) are currently trading at $10.90, up $1.60 or 17.20% Tuesday morning. The stock has been trading in the range of $5.25 - $14.48 for the past one year. Trading volume is rising over 407K versus an average volume of 289K shares. RTTNews

Sep 24, 2020

08:30AM EDT Spero Therapeutics Hosting Key Opinion Leader Call on Oral GlobeNewswire Inc

Sep 15, 2020

08:00AM EDT Spero Therapeutics to Present at Investor Conferences in September GlobeNewswire Inc

Sep 11, 2020

06:59AM EDT Spero Therapeutics Prices 4.785M Share Common Stock Offering, 3.215M Share Of Non-Voting Series D Convertible Preferred Stock for Gross Proceeds $80M Benzinga

06:54AM EDT Spero Therapeutics Announces Pricing of Securities Offering GlobeNewswire Inc

Sep 10, 2020

02:31PM EDT Mid-Afternoon Market Update: Nasdaq Tumbles 200 Points; Satsuma Pharmaceuticals Shares Plunge Benzinga

06:06AM EDT A Peek Into The Markets: US Stock Futures Down Ahead Of Initial Jobless Claims Data Benzinga

Sep 9, 2020

04:33PM EDT Spero Therapeutics Announces Proposed Public Offering GlobeNewswire Inc

04:33PM EDT Spero Therapeutics Announces A 8M Share Common Stock Offering Benzinga

Sep 8, 2020

11:07AM EDT Shares of Spero Therapeutics, Inc. (SPRO) are currently gaining over 15% on Tuesday morning after the company announced positive results from a late stage trial for urinary tract infection treatment. RTTNews

07:41AM EDT Spero Therapeutics Announces Positive Topline Results From Phase 3 ADAPT-PO Clinical Trial Of Oral Tebipenem HBr RTTNews

07:31AM EDT Spero Therapeutics Announces Phase 3 ADAPT-PO Clinical Trial Of Oral Tebipenem HBr Met Primary Endpoint Benzinga

07:30AM EDT Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract infection and acute pyelonephritis GlobeNewswire Inc

Sep 1, 2020

03:18PM EDT Plasma Stocks Quiet; Reuters Reports NIH Advisors Say Data Fail To Back Trump-Backed Plasma Therapy Benzinga

Aug 31, 2020

08:04AM EDT Spero Therapeutics Announces FDA Acceptance Of IND Application For SPR720 For NTM Pulmonary Disease RTTNews

08:00AM EDT Spero Therapeutics Announces FDA Acceptance Of IND Application for SPR720 Benzinga

08:00AM EDT Spero Therapeutics Announces FDA Acceptance of IND Application for GlobeNewswire Inc

Aug 6, 2020

04:50PM EDT Spero Therapeutics Q2 EPS $(0.85) Beats $(1.12) Estimate, Sales $1.73M Miss $3.40M Estimate Benzinga

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

Jul 31, 2020

05:04PM EDT Spero Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Jul 29, 2020

04:01PM EDT Spero Therapeutics to Provide Business Update and Report Second GlobeNewswire Inc